Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and/or pneumococcal diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

Abstract: Compounds of formula (I) are made, wherein W1, W2, W3, W4, R1, R2, R3, R4, R5, R6 and m have the meaning as described herein. The compounds are SRPK inhibitors and can be used, inter alia, for the treatment of hyperproliferative disorders. A medicament and a pharmaceutical composition are made that include the compound of formula (I). Methods are developed for treating a disease caused, mediated, and/or propagated by SRPK activity, for preparing a medicament for the treatment thereof, and for inhibiting SRPK.

Abstract: Substituted tetrazole derivatives are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.

Abstract: The present invention relates to a process for the preparation of a solid pharmaceutical administration form comprising mesoporous silica using a 3D printing process. The process is a printing process that allows the production of solid pharmaceutical administration forms comprising drug loaded mesoporous silica in an easy and flexible manner and in conformity with the high-quality standards required for the production of pharmaceutical.

Abstract: A compound of Formula I or pharmaceutically acceptable compositions thereof, is useful to as a TLR7/8 antagonist.

Abstract: A method is described for producing a pneumococcal capsular polysaccharide protein conjugate in which one or more activated pneumococcal polysaccharides of particular pneumococcal serotypes and carrier protein are separately lyophilized in the form of lyospheres of carrier protein and lyospheres of the one or more polysaccharides. A predetermined amount of carrier protein lyospheres and activated polysaccharide lyospheres are mixed together and the mixture reconstituted in an organic solvent to produce polysaccharide carrier protein conjugates. A plurality of conjugates, each comprising polysaccharides of a particular serotype, may be used to produce multivalent pneumococcal immunogenic compositions having a combination of conjugates for use in vaccines.

Abstract: A liquid-crystalline medium, preferably having a nematic phase, comprising one or more compounds of formula C the use thereof in an energy-efficient electro-optical display, particularly in an active-matrix display based on the IPS or FFS effect, displays of this type which contain a liquid-crystalline medium of this type, and the use of the compounds of formula C for improvement of the contrast and/or response times of a liquid-crystalline medium which comprises one or more additional mesogenic compounds.

Abstract: A novel treatment regimen is provided for the treatment of autoimmune disorders. Said novel treatment regimen provides for an efficacious treatment of autoimmune disorders with an advantageous safety profile and/or a high quality of life for the patient. Said novel treatment regimen provides for an advantageous benefit-risk ratio for patients endangered by the risk of infections.

Abstract: The present invention is directed to nucleic acids and related immunogenic polypeptides for the prevention or treatment of infectious diseases. In particular, the nucleic acids and immunogenic polypeptides provide utility for the prophylactic prevention of norovirus infections in a mammal. The invention is further directed to nucleic acid-based vaccine compositions and a kit of parts comprising the vaccine compositions, as well as methods of treatment and medical uses relating to the nucleic acids, vaccine compositions, and kit of parts.

Abstract: An electronic element (10) comprising a plurality of cells (100) arranged in a three dimensional array of cells (100) is provided, wherein the cells (100) are located at crossings between two crossed electrode lines (30, 31). Each cell (100) of the electronic component (100) comprises in this order a first electrode (102), a part (104) of a molecular layer (20) and a second electrode (106), wherein the molecular layer (20) is a self-assembled monolayer of organic molecules having an anchoring group connected to a dipolar unit by means of a conformationally flexible unit. Further aspects of the invention relate to a method and a compound for producing such an electronic element (10) and the use of such an electronic element (10).

Abstract: The present invention relates to methods for treating diseases and conditions characterised by aberrant cell growth, e.g., cancers, comprising administering a combination of a DNA repair inhibitor and a molecular targeted radioimmunotherapeutic agent.

Abstract: The invention described herein relates to a high-throughput and multiplex Streptococcus pneumoniae (S. pneumoniae) serotype (ST)-specific polymerase chain reaction-pneumococcal antigen detection (PCR-PAD) assay useful to support epidemiology studies, clinical trials and clinical therapy. The invention further provides kits for detecting the presence or absence of S. pneumoniae and the presence or absence of particular S. pneumoniae strains in a patient sample.

Abstract: The present invention relates to a compound of the formula (1), to the use of the compound in an electronic device, and to an electronic device comprising a compound of the formula (1). The present invention furthermore relates to a process for the preparation of a compound of the formula (1) and to a formulation comprising one or more compounds of the formula (1).

Abstract: Liquid-crystalline (LC) media having positive dielectric anisotropy and liquid-crystal displays (LCDs) containing these media, especially displays addressed by an active matrix and in particular to LC displays of the TN, PS-TN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, HB-FFS, XB-FFS, PS-FFS, SA-HB-FFS, SA-XB-FFS, polymer stabilised SA-HB-FFS, polymer stabilised SA-XB-FFS, positive VA or positive PS-VA type.

Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ? 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.

Abstract: A light valve that is operable in and electrically switchable between an optically clear and transparent state and an opaque state, wherein one or more polymerisable mesogenic compounds provided in a layer containing a liquid-crystalline medium that comprises one or more mesogenic compounds, one or more chiral compounds, one or more dichroic dyes and the one or more polymerisable mesogenic compounds are subjected to photopolymerisation. Further, a liquid-crystalline medium used in the method, a light valve obtained or respectively obtainable by carrying out the method, and the use of the light valve in mobile devices.

Abstract: Liquid crystal (LC) media having negative dielectric anisotropy, the use thereof in an electro-optical display, particularly in a display with passive matrix addressing, based on the VA, ECB, FFS or IPS effect, and displays of this type, in particular an energy saving PM-VA display with low duty driving.

Abstract: TROP2 binders and variants thereof are described. In a specific embodiment, the TROP2 binders that are antibodies that preferentially bind high-expressing TROP2 cells over low-expressing TROP2 cells and conjugates thereof comprising the TROP2 binders conjugated to a payload are described.

Abstract: The present invention relates to immunoglobulins that specifically bind MMP13 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit an activity of MMP13 and preferably are also stable.